综述 |
|
|
|
|
肿瘤靶向细菌Escherichia coli Nissle 1917在癌症治疗中的研究进展* |
李雨桐,崔天琦,张海林,于广乐,栾霁**(),王海龙**() |
山东大学微生物技术国家重点实验室 微生物技术研究院 青岛 266237 |
|
Research Advances in Tumor-targeting Bacteria Escherichia coli Nissle 1917 in Cancer Therapy |
LI Yu-tong,CUI Tian-qi,ZHANG Hai-lin,YU Guang-le,LUAN Ji**(),WANG Hai-long**() |
State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao 266237, China |
引用本文:
李雨桐, 崔天琦, 张海林, 于广乐, 栾霁, 王海龙. 肿瘤靶向细菌Escherichia coli Nissle 1917在癌症治疗中的研究进展*[J]. 中国生物工程杂志, 2023, 43(6): 54-68.
LI Yu-tong, CUI Tian-qi, ZHANG Hai-lin, YU Guang-le, LUAN Ji, WANG Hai-long. Research Advances in Tumor-targeting Bacteria Escherichia coli Nissle 1917 in Cancer Therapy. China Biotechnology, 2023, 43(6): 54-68.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2301036
或
https://manu60.magtech.com.cn/biotech/CN/Y2023/V43/I6/54
|
[1] |
Yi C, Huang Y, Guo Z Y, et al. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacologica Sinica, 2005, 26(5): 629-634.
doi: 10.1111/j.1745-7254.2005.00094.x
|
[2] |
Van Mellaert L, Barbé S, Anné J. Clostridium spores as anti-tumour agents. Trends in Microbiology, 2006, 14(4): 190-196.
pmid: 16500103
|
[3] |
Thamm D, Kurzman I, King I, et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clinical Cancer Research, 2005, 11: 4827-4834.
doi: 10.1158/1078-0432.CCR-04-2510
|
[4] |
Stritzker J, Weibel S, Hill P J, et al. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. International Journal of Medical Microbiology, 2007, 297(3): 151-162.
doi: 10.1016/j.ijmm.2007.01.008
|
[5] |
Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science, 2020, 368(6494): 973-980.
doi: 10.1126/science.aay9189
pmid: 32467386
|
[6] |
Sepich-Poore G D, Zitvogel L, Straussman R, et al. The microbiome and human cancer. Science, 2021, 371(6536): eabc4552.
doi: 10.1126/science.abc4552
|
[7] |
Poore G D, Kopylova E, Zhu Q Y, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature, 2020, 579(7800): 567-574.
doi: 10.1038/s41586-020-2095-1
|
[8] |
Kramer M G, Masner M, Ferreira F A, et al. Bacterial therapy of cancer: promises, limitations, and insights for future directions. Frontiers in Microbiology, 2018, 9: 16.
doi: 10.3389/fmicb.2018.00016
pmid: 29472896
|
[9] |
Na H S, Kim H J, Lee H C, et al. Immune response induced by Salmonella typhimurium defective in ppGpp synthesis. Vaccine, 2006, 24(12): 2027-2034.
doi: 10.1016/j.vaccine.2005.11.031
|
[10] |
Brockstedt D G, Giedlin M A, Leong M L, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(38): 13832-13837.
|
[11] |
Harimoto T, Hahn J, Chen Y Y, et al. A programmable encapsulation system improves delivery of therapeutic bacteria in mice. Nature Biotechnology, 2022, 40(8): 1259-1269.
doi: 10.1038/s41587-022-01244-y
pmid: 35301496
|
[12] |
Din M O, Danino T, Prindle A, et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature, 2016, 536(7614): 81-85.
doi: 10.1038/nature18930
|
[13] |
Zhao M, Yang M, Li X M, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102(3): 755-760.
|
[14] |
Felgner S, Frahm M, Kocijancic D, et al. aroA-deficient Salmonella enterica serovar typhimurium is more than a metabolically attenuated mutant. mBio, 2016, 7(5): e01220-16.
|
[15] |
Leventhal D S, Sokolovska A, Li N, et al. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nature Communications, 2020, 11: 2739.
doi: 10.1038/s41467-020-16602-0
pmid: 32483165
|
[16] |
Yu B, Yang M, Shi L, et al. Explicit hypoxia targeting with tumor suppression by creating an “obligate” anaerobic Salmonella typhimurium strain. Scientific Reports, 2012, 2(1): 1-10.
|
[17] |
Bereta M, Hayhurst A, Gajda M, et al. Improving tumor targeting and therapeutic potential of Salmonella VNP 20009 by displaying cell surface CEA-specific antibodies. Vaccine, 2007, 25(21): 4183-4192.
doi: 10.1016/j.vaccine.2007.03.008
|
[18] |
Park S H, Zheng J H, Nguyen V H, et al. RGD peptide cell-surface display enhances the targeting and therapeutic efficacy of attenuated Salmonella-mediated cancer therapy. Theranostics, 2016, 6(10): 1672-1682.
doi: 10.7150/thno.16135
|
[19] |
Geng Z M, Cao Z P, Liu R, et al. Aptamer-assisted tumor localization of bacteria for enhanced biotherapy. Nature Communications, 2021, 12: 6584.
doi: 10.1038/s41467-021-26956-8
pmid: 34782610
|
[20] |
Clairmont C, Lee K C, Pike J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimuvium. The Journal of Infectious Diseases, 2000, 181(6): 1996-2002.
doi: 10.1086/jid.2000.181.issue-6
|
[21] |
Liang K, Liu Q, Li P, et al. Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models. Cancer Gene Therapy, 2018, 25(7): 167-183.
doi: 10.1038/s41417-018-0021-6
|
[22] |
Chiang C J, Hong Y H. In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy. Scientific Reports, 2021, 11: 18172.
doi: 10.1038/s41598-021-97457-3
|
[23] |
Chiang C J, Huang P H. Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors. Scientific Reports, 2021, 11: 5853.
doi: 10.1038/s41598-021-85372-6
|
[24] |
Friedlos F, Lehouritis P, Ogilvie L, et al. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Clinical Cancer Research, 2008, 14: 4259-4266.
doi: 10.1158/1078-0432.CCR-07-4800
pmid: 18594008
|
[25] |
Cheng C M, Lu Y L, Chuang K H, et al. Tumor-targeting prodrug-activating bacteria for cancer therapy. Cancer Gene Therapy, 2008, 15(6): 393-401.
doi: 10.1038/cgt.2008.10
pmid: 18369382
|
[26] |
Ho C L, Tan H Q, Chua K J, et al. Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. Nature Biomedical Engineering, 2018, 2(1): 27-37.
doi: 10.1038/s41551-017-0181-y
pmid: 31015663
|
[27] |
He L, Yang H J, Liu F, et al. Escherichia coli Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth. Oncotarget, 2017, 8(49): 85772-85782.
doi: 10.18632/oncotarget.v8i49
|
[28] |
Xie S Z, Zhao L, Song X J, et al. Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release. Journal of Controlled Release, 2017, 268: 390-399.
doi: 10.1016/j.jconrel.2017.10.041
|
[29] |
Zoaby N, Shainsky-Roitman J, Badarneh S, et al. Autonomous bacterial nanoswimmers target cancer. Journal of Controlled Release, 2017, 257: 68-75.
doi: S0168-3659(16)30940-3
pmid: 27744036
|
[30] |
Van Du Nguyen, Han J W, Choi Y J, et al. Active tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with targeting bacteria (Salmonella typhimurium). Sensors and Actuators B: Chemical, 2016, 224: 217-224.
doi: 10.1016/j.snb.2015.09.034
|
[31] |
Yoon W, Park Y C, Kim J, et al. Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma. European Journal of Cancer, 2017, 70: 48-61.
doi: 10.1016/j.ejca.2016.10.010
|
[32] |
Loeffler M, Le’Negrate G, Krajewska M, et al. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104(31): 12879-12883.
|
[33] |
al-Ramadi B K, Fernandez-Cabezudo M J, El-Hasasna H, et al. Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clinical Immunology, 2009, 130(1): 89-97.
doi: 10.1016/j.clim.2008.08.021
pmid: 18849195
|
[34] |
Chowdhury S, Castro S, Coker C, et al. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nature Medicine, 2019, 25(7): 1057-1063.
doi: 10.1038/s41591-019-0498-z
pmid: 31270504
|
[35] |
Gurbatri C R, Lia I, Vincent R, et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Science Translational Medicine, 2020, 12(530): eaax0876.
doi: 10.1126/scitranslmed.aax0876
|
[36] |
Gao G Q, Ma T, Zhang T, et al. Adjunctive probiotic Lactobacillus rhamnosus probio-M9 administration enhances the effect of anti-PD-1 antitumor therapy via restoring antibiotic-disrupted gut microbiota. Frontiers in Immunology, 2021, 12: 772532.
doi: 10.3389/fimmu.2021.772532
|
[37] |
Selvanesan B C, Chandra D, Quispe-Tintaya W, et al. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Science Translational Medicine, 2022, 14(637): eabc1600.
doi: 10.1126/scitranslmed.abc1600
|
[38] |
Chen F M, Zang Z S, Chen Z, et al. Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy. Biomaterials, 2019, 214: 119226.
doi: 10.1016/j.biomaterials.2019.119226
|
[39] |
Fan J X, Li Z H, Liu X H, et al. Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α expression via oral administration. Nano Letters, 2018, 18(4): 2373-2380.
doi: 10.1021/acs.nanolett.7b05323
|
[40] |
Chen W F, Guo Z F, Zhu Y N, et al. Combination of bacterial-photothermal therapy with an anti-PD-1 peptide depot for enhanced immunity against advanced cancer. Advanced Functional Materials, 2020, 30(1): 1906623.
doi: 10.1002/adfm.v30.1
|
[41] |
Li J J, Xia Q, Guo H Y, et al. Frontispiece:decorating bacteria with triple immune nanoactivators generates tumor-resident living immunotherapeutics. Angewandte Chemie International Edition, 2022, 61(27): e202282762.
|
[42] |
Wang L, Cao Z P, Zhang M M, et al. Spatiotemporally controllable distribution of combination therapeutics in solid tumors by dually modified bacteria. Advanced Materials, 2022, 34(1): 2106669.
doi: 10.1002/adma.v34.1
|
[43] |
Liu L L, He H M, Luo Z Y, et al. In situ photocatalyzed oxygen generation with photosynthetic bacteria to enable robust immunogenic photodynamic therapy in triple-negative breast cancer. Advanced Functional Materials, 2020, 30(10): 1910176.
doi: 10.1002/adfm.v30.10
|
[44] |
Yan S Q, Zeng X M, Wang Y, et al. Biomineralization of bacteria by a metal-organic framework for therapeutic delivery. Advanced Healthcare Materials, 2020, 9(12): 2000046.
doi: 10.1002/adhm.v9.12
|
[45] |
Grozdanov L, Zähringer U, Blum-Oehler G, et al. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain nissle 1917. Journal of Bacteriology, 2002, 184(21): 5912-5925.
doi: 10.1128/JB.184.21.5912-5925.2002
pmid: 12374825
|
[46] |
Sturm A, Rilling K, Baumgart D C, et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infection and Immunity, 2005, 73(3): 1452-1465.
doi: 10.1128/IAI.73.3.1452-1465.2005
|
[47] |
Arribas B, Rodríguez-Cabezas M, Camuesco D, et al. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. British Journal of Pharmacology, 2009, 157(6): 1024-1033.
doi: 10.1111/j.1476-5381.2009.00270.x
pmid: 19486007
|
[48] |
Chua K J, Kwok W C, Aggarwal N, et al. Designer probiotics for the prevention and treatment of human diseases. Current Opinion in Chemical Biology, 2017, 40: 8-16.
doi: S1367-5931(17)30050-9
pmid: 28478369
|
[49] |
Singh B, Mal G, Marotta F. Designer probiotics: paving the way to living therapeutics. Trends in Biotechnology, 2017, 35(8): 679-682.
doi: S0167-7799(17)30082-3
pmid: 28483159
|
[50] |
Shen H K, Zhao Z T, Zhao Z J, et al. Native and engineered probiotics: promising agents against related systemic and intestinal diseases. International Journal of Molecular Sciences, 2022, 23(2): 594.
doi: 10.3390/ijms23020594
|
[51] |
王彦雯, 叶静怡, 王鹏超. 合成生物学在E.coli Nissle 1917靶向治疗癌症中的应用. 中国生物化学与分子生物学报, 2021, 37(1): 20-28.
|
|
Wang Y W, Ye J Y, Wang P C. Application of synthetic biology in targeted cancer therapies by E.coli Nissle 1917. Chinese Journal of Biochemistry and Molecular Biology, 2021, 37(1): 20-28.
|
[52] |
Fischbach M A, Bluestone J A, Lim W A. Cell-based therapeutics: the next pillar of medicine. Science Translational Medicine, 2013, 5(179): e3005568.
|
[53] |
Weber W, Fussenegger M. Emerging biomedical applications of synthetic biology. Nature Reviews Genetics, 2012, 13(1): 21-35.
doi: 10.1038/nrg3094
|
[54] |
Wu M R, Jusiak B, Lu T K. Engineering advanced cancer therapies with synthetic biology. Nature Reviews Cancer, 2019, 19(4): 187-195.
|
[55] |
Forbes N S. Engineering the perfect (bacterial) cancer therapy. Nature Reviews Cancer, 2010, 10(11): 785-794.
doi: 10.1038/nrc2934
pmid: 20944664
|
[56] |
Zhou S B, Gravekamp C, Bermudes D, et al. Tumour-targeting bacteria engineered to fight cancer. Nature Reviews Cancer, 2018, 18(12): 727-743.
doi: 10.1038/s41568-018-0070-z
pmid: 30405213
|
[57] |
Piñero-Lambea C, Ruano-Gallego D, Fernández L Á. Engineered bacteria as therapeutic agents. Current Opinion in Biotechnology, 2015, 35: 94-102.
doi: 10.1016/j.copbio.2015.05.004
pmid: 26070111
|
[58] |
Pedrolli D B, Ribeiro N V, Squizato P N, et al. Engineering microbial living therapeutics: the synthetic biology toolbox. Trends in Biotechnology, 2019, 37(1): 100-115.
doi: S0167-7799(18)30258-0
pmid: 30318171
|
[59] |
Chien T, Doshi A, Danino T. Advances in bacterial cancer therapies using synthetic biology. Current Opinion in Systems Biology, 2017, 5: 1-8.
doi: 10.1016/j.coisb.2017.05.009
pmid: 29881788
|
[60] |
Wu F, Liu J Y. Decorated bacteria and the application in drug delivery. Advanced Drug Delivery Reviews, 2022, 188: 114443.
doi: 10.1016/j.addr.2022.114443
|
[61] |
Youn W, Kim J Y, Park J, et al. Single-cell nanoencapsulation: from passive to active shells. Advanced Materials, 2020, 32(35): 1907001.
doi: 10.1002/adma.v32.35
|
[62] |
Centurion F, Basit A W, Liu J Y, et al. Nanoencapsulation for probiotic delivery. ACS Nano, 2021, 15(12): 18653-18660.
doi: 10.1021/acsnano.1c09951
pmid: 34860008
|
[63] |
Niβle A. Weiteres über grundlagen und Praxis der mutaflorbehandlung. DMW - Deutsche Medizinische Wochenschrift, 1925, 51(44): 1809-1813.
doi: 10.1055/s-0028-1137292
|
[64] |
Ou B M, Yang Y, Tham W L, et al. Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application. Applied Microbiology and Biotechnology, 2016, 100(20): 8693-8699.
doi: 10.1007/s00253-016-7829-5
|
[65] |
Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004, 53(11): 1617-1623.
doi: 10.1136/gut.2003.037747
pmid: 15479682
|
[66] |
Sonnenborn U. Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiology Letters, 2016, 363(19): fnw212.
doi: 10.1093/femsle/fnw212
|
[67] |
Wassenaar T M. Insights from 100 years of research with probiotic E. coli. European Journal of Microbiology and Immunology, 2016, 6(3): 147-161.
pmid: 27766164
|
[68] |
Reister M, Hoffmeier K, Krezdorn N, et al. Complete genome sequence of the Gram-negative probiotic Escherichia coli strain Nissle 1917. Journal of Biotechnology, 2014, 187: 106-107.
doi: 10.1016/j.jbiotec.2014.07.442
pmid: 25093936
|
[69] |
Sonnenborn U, Schulze J. The non-pathogenic Escherichia coli strain Nissle 1917-features of a versatile probiotic. Microbial Ecology in Health and Disease, 2009, 21(3-4): 122-158.
doi: 10.3109/08910600903444267
|
[70] |
Zhang Y L, Ji W, He L, et al. E. coli Nissle 1917-derived minicells for targeted delivery of chemotherapeutic drug to hypoxic regions for cancer therapy. Theranostics, 2018, 8(6): 1690-1705.
doi: 10.7150/thno.21575
|
[71] |
Zhang Y L, Zhang Y M, Xia L Q, et al. Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Applied and Environmental Microbiology, 2012, 78(21): 7603-7610.
doi: 10.1128/AEM.01390-12
|
[72] |
Yu X L, Lin C S, Yu J, et al. Bioengineered Escherichia coli Nissle 1917 for tumour-targeting therapy. Microbial Biotechnology, 2020, 13(3): 629-636.
doi: 10.1111/mbt2.v13.3
|
[73] |
Grozdanov L, Raasch C, Schulze J, et al. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. Journal of Bacteriology, 2004, 186(16): 5432-5441.
doi: 10.1128/JB.186.16.5432-5441.2004
pmid: 15292145
|
[74] |
Hacker J, Carniel E. Ecological fitness, genomic islands and bacterial pathogenicity. EMBO Reports, 2001, 2(5): 376-381.
doi: 10.1093/embo-reports/kve097
pmid: 11375927
|
[75] |
van der Hooft J J J, Goldstone R J, Harris S, et al. Substantial extracellular metabolic differences found between phylogenetically closely related probiotic and pathogenic strains of Escherichia coli. Frontiers in Microbiology, 2019, 10: 252.
doi: 10.3389/fmicb.2019.00252
|
[76] |
Behnsen J, Deriu E, Sassone-Corsi M, et al. Probiotics: properties, examples, and specific applications. Cold Spring Harbor Perspectives in Medicine, 2013, 3(3): a010074.
|
[77] |
Hafez M, Hayes K, Goldrick M, et al. The K5 capsule of Escherichia coli strain nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction. Infection and Immunity, 2009, 77(7): 2995-3003.
doi: 10.1128/IAI.00040-09
|
[78] |
Hafez M, Hayes K, Goldrick M, et al. The K5 capsule of Escherichia coli strain Nissle 1917 is important in stimulating expression of toll-like receptor 5, CD14, MyD88, and TRIF together with the induction of interleukin-8 expression via the mitogen-activated protein kinase pathway in epithelial cells. Infection and Immunity, 2010, 78(5): 2153-2162.
doi: 10.1128/IAI.01406-09
|
[79] |
Nzakizwanayo J, Kumar S, Ogilvie L A, et al. Disruption of Escherichia coli Nissle 1917 K5 capsule biosynthesis, through loss of distinct kfi genes, modulates interaction with intestinal epithelial cells and impact on cell health. PLoS One, 2015, 10(3): e0120430.
doi: 10.1371/journal.pone.0120430
|
[80] |
Li R J, Helbig L, Fu J, et al. Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy. Research in Microbiology, 2019, 170(2): 74-79.
doi: 10.1016/j.resmic.2018.11.001
|
[81] |
Xie S Z, Chen M H, Song X J, et al. Bacterial microbots for acid-labile release of hybrid micelles to promote the synergistic antitumor efficacy. Acta Biomaterialia, 2018, 78: 198-210.
doi: S1742-7061(18)30442-2
pmid: 30036720
|
[82] |
Xie S Z, Zhang P, Zhang Z L, et al. Bacterial navigation for tumor targeting and photothermally-triggered bacterial ghost transformation for spatiotemporal drug release. Acta Biomaterialia, 2021, 131: 172-184.
doi: 10.1016/j.actbio.2021.06.030
pmid: 34171461
|
[83] |
Abedi M H, Yao M S, Mittelstein D R, et al. Ultrasound-controllable engineered bacteria for cancer immunotherapy. Nature Communications, 2022, 13: 1585.
doi: 10.1038/s41467-022-29065-2
pmid: 35332124
|
[84] |
Chen J H, Li X H, Liu Y M, et al. Engineering a probiotic strain of Escherichia coli to induce the regression of colorectal cancer through production of 5-aminolevulinic acid. Microbial Biotechnology, 2021, 14(5): 2130-2139.
doi: 10.1111/mbt2.v14.5
|
[85] |
Canale F P, Basso C, Antonini G, et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature, 2021, 598(7882): 662-666.
doi: 10.1038/s41586-021-04003-2
|
[86] |
Huang C Y, Wang F B, Liu L, et al. Hypoxic tumor radiosensitization using engineered probiotics. Advanced Healthcare Materials, 2021, 10(10): 2002207.
doi: 10.1002/adhm.v10.10
|
[87] |
Geiger R, Rieckmann J C, Wolf T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell, 2016, 167(3): 829-842.e13.
doi: S0092-8674(16)31313-7
pmid: 27745970
|
[88] |
张悦, 邢仕歌, 王震, 等. 核酸适配体在靶向药物传递中的研究进展. 生物化学与生物物理进展, 2015, 42(3): 236-243.
|
|
Zhang Y, Xing S G, Wang Z, et al. Recent research of aptamer in target drug delivery. China Industrial Economics, 2015, 42(3): 236-243.
|
[89] |
Cao Z P, Cheng S S, Wang X Y, et al. Camouflaging bacteria by wrapping with cell membranes. Nature Communications, 2019, 10: 3452.
doi: 10.1038/s41467-019-11390-8
pmid: 31388002
|
[90] |
Feng P P, Cao Z P, Wang X Y, et al. On-demand bacterial reactivation by restraining within a triggerable nanocoating. Advanced Materials, 2020, 32(34): 2002406.
doi: 10.1002/adma.v32.34
|
[91] |
Liu Y, Zhang M M, Wang X Y, et al. Dressing bacteria with a hybrid immunoactive nanosurface to elicit dual anticancer and antiviral immunity. Advanced Materials, 2023, 35(11): 2210949.
doi: 10.1002/adma.v35.11
|
[92] |
林思思, 潘超, 张一帆, 等. 基于表面涂层益生菌的肿瘤抗原口服递送系统. 合成生物学, 2022(4): 810-820.
doi: 10.12211/2096-8280.2022-010
|
|
Lin S S, Pan C, Zhang Y F, et al. Coated probiotic-based drug carriers for oral delivery of tumor antigens. Synthetic Biology Journal, 2022(4): 810-820.
doi: 10.12211/2096-8280.2022-010
|
[93] |
Lehouritis P, Stanton M, McCarthy F O, et al. Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria. Journal of Controlled Release, 2016, 222: 9-17.
doi: 10.1016/j.jconrel.2015.11.030
pmid: 26655063
|
[94] |
Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Letters, 2012, 320(2): 130-137
doi: 10.1016/j.canlet.2012.03.008
pmid: 22425960
|
[95] |
He L, Yang H J, Tang J L, et al. Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy. Journal of Biological Engineering, 2019, 13(1): 1-13.
doi: 10.1186/s13036-018-0125-4
|
[96] |
Drummond D C, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacological Reviews, 1999, 51(4): 691-743.
pmid: 10581328
|
[97] |
Webb B A, Chimenti M, Jacobson M P, et al. Dysregulated pH: a perfect storm for cancer progression. Nature Reviews Cancer, 2011, 11(9): 671-677.
doi: 10.1038/nrc3110
pmid: 21833026
|
[98] |
Zhou J H, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nature Reviews Drug Discovery, 2017, 16(3): 181-202.
doi: 10.1038/nrd.2016.199
pmid: 27807347
|
[99] |
崔超, 涂强, 张友明. 细菌用于靶向治疗肿瘤的研究进展. 中国抗生素杂志, 2021, 46(5):388-395.
|
|
Cui C, Tu Q, Zhang Y M. Advances in bacteria for tumor-targeting therapy. Chinese Journal of Antibiotics, 2021, 46(5):388-395.
|
[100] |
Wu L Y, Bao F F, Li L, et al. Bacterially mediated drug delivery and therapeutics: strategies and advancements. Advanced Drug Delivery Reviews, 2022, 187: 114363.
doi: 10.1016/j.addr.2022.114363
|
[101] |
Yang E, Qian W P, Cao Z H, et al. Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery. Theranostics, 2015, 5(1): 43-61.
doi: 10.7150/thno.10350
pmid: 25553097
|
[102] |
Cheng T J, Liu J J, Ren J, et al. Green tea catechin-based complex micelles combined with doxorubicin to overcome cardiotoxicity and multidrug resistance. Theranostics, 2016, 6(9): 1277-1292.
doi: 10.7150/thno.15133
pmid: 27375779
|
[103] |
Postow M A, Callahan M K, Wolchok J D. Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology, 2015, 33(17): 1974-1982.
doi: 10.1200/JCO.2014.59.4358
pmid: 25605845
|
[104] |
Gerard C L, Delyon J, Wicky A, et al. Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treatment Reviews, 2021, 101: 102227.
doi: 10.1016/j.ctrv.2021.102227
|
[105] |
Appleton E, Hassan J, Chan Wah Hak C, et al. Kickstarting immunity in cold tumours: localised tumour therapy combinations with immune checkpoint blockade. Frontiers in Immunology, 2021, 12: 754436.
doi: 10.3389/fimmu.2021.754436
|
[106] |
Tang Q, Peng X, Xu B, et al. Current status and future directions of bacteria-based immunotherapy. Frontiers in Immunology, 2022, 13: 911783.
doi: 10.3389/fimmu.2022.911783
|
[107] |
Ribas A, Wolchok J D. Cancer immunotherapy using checkpoint blockade. Science, 2018, 359(6382): 1350-1355.
doi: 10.1126/science.aar4060
pmid: 29567705
|
[108] |
Gu J, Wu A W, Li J Y, et al. An assessment of World Health Organization criteria for severe acute respiratory syndrome in patients with cancer. Cancer, 2004, 100(7): 1374-1378.
pmid: 15042670
|
[109] |
Corrales L, Glickman L H, McWhirter S M, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Reports, 2015, 11(7): 1018-1030.
doi: 10.1016/j.celrep.2015.04.031
pmid: 25959818
|
[110] |
Lin M J, Svensson-Arvelund J, Lubitz G S, et al. Cancer vaccines: the next immunotherapy frontier. Nature Cancer, 2022, 3(8): 911-926.
doi: 10.1038/s43018-022-00418-6
pmid: 35999309
|
[111] |
Zhen X, Cheng P H, Pu K Y. Recent advances in cell membrane-camouflaged nanoparticles for cancer phototherapy. Small, 2019, 15(1): 1804105.
doi: 10.1002/smll.v15.1
|
[112] |
郭弘, 李霞, 瞿鼎, 等. Fe基金属-有机框架在抗肿瘤药物递送方面的研究进展. 药学学报, 2022, 57(5): 1252-1262.
|
|
Guo H, Li X, Qu D, et al. Research progress on Fe-based metal-organic frameworks in antitumor drug delivery. Acta Pharmaceutica Sinica, 2022, 57(5): 1252-1262.
|
[113] |
Lin D W, Feng X L, Mai B J, et al. Bacterial-based cancer therapy: an emerging toolbox for targeted drug/gene delivery. Biomaterials, 2021, 277: 121124.
doi: 10.1016/j.biomaterials.2021.121124
|
[114] |
Zhang N, Song J, Liu Y, et al. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma. Journal of Controlled Release, 2019, 306: 15-28.
doi: S0168-3659(19)30300-1
pmid: 31132380
|
[115] |
Luo L H, Zhu C Q, Yin H, et al. Laser immunotherapy in combination with perdurable PD-1 blocking for the treatment of metastatic tumors. ACS Nano, 2018, 12(8): 7647-7662.
doi: 10.1021/acsnano.8b00204
pmid: 30020768
|
[116] |
Dougherty T J, Gomer C J, Henderson B W, et al. Photodynamic therapy. JNCI: Journal of the National Cancer Institute, 1998, 90(12): 889-905.
doi: 10.1093/jnci/90.12.889
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|